article thumbnail

Does DIY still have a place in diabetes care? 

STAT

When Dana Lewis built her first artificial pancreas in 2014, she — and millions of other people with type 1 diabetes — didn’t have another option. Since then, the community of DIYers with type 1 diabetes has grown to the thousands.

Diabetes 231
article thumbnail

STAT+: For Parkinson’s disease, advances spurred by Apple Watch offer a glimmer of hope

STAT

Since the Apple Watch was unveiled in 2014, it has been trumpeted not only as a high tech fashion accessory, but also as a way for people to track their own health and fitness. It has evolved as a popular cardio tool for such uses as heart rate monitoring, recording your ECG, and measuring the oxygen saturation of your blood.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Keeping Up with Recent Diabetes Therapies (Diabetes Mellitus)

PharmaShots

Shots: With an incurable nature and hefty medication costs, diabetes mellitus remains a global health concern and the seventh leading cause of death across the world. Diabetes, aka diabetes mellitus is a condition that arises when the pancreas fails to produce enough insulin or the cells of the body do not respond to the insulin produced.

article thumbnail

The US FDA Approves Boehringer Ingelheim’s Jardiance and Synjardy for the Treatment of Type 2 Diabetes

PharmaShots

Jardiance & Synjardy was approved in the US in 2014 & 2015, respectively. Ref: PR Newswire | Image: Boehringer Ingelheim Related News:- Eli Lilly Reports the US FDA’s Acceptance of sNDA for Jardiance to Treat Type 2 Diabetes PharmaShots! 52 patients had an average 0.2% decrease in hemoglobin A1c over 0.7%

article thumbnail

FDA accepts Lilly-Boehringer Ingelheim’ sNDA for Jardiance

Pharmaceutical Technology

Jardiance was initially approved in 2014 as a once-a-day tablet for use with diet and exercise to reduce blood sugar in type 2 diabetes adult patients. It has also been approved for reducing cardiovascular death risk in type 2 diabetes and known cardiovascular disease adult patients.

Diabetes 105
article thumbnail

IsomAb secures funds to advance peripheral arterial disease treatment

Pharmaceutical Business Review

ISM-001 is a high-affinity, humanised antibody aimed at restoring blood flow in patients with diabetic vascular disease. IsomAb CEO Jackie Turnbull said: “IsomAb’s lead programme targeting VEGF-A 165 b aims to treat peripheral arterial disease in the large proportion of patients with concomitant metabolic syndrome and Type II diabetes. “We

article thumbnail

Dyslipidemia

RX Note

The common cardiovascular risk factors include: Dyslipidemia Hypertension Diabetes Mellitus Smoking Overweight/obesity Dyslipidemia Dyslipidemia refers to the following lipid levels: Total cholesterol (TC) > 5.2 Patients with established CVD, CKD and diabetes fall into the very high and high risk categories.